Slide 1: Webinar to Discuss Carina CAR-T Collaboration
25 August 2021 ASX Announcement WEBINAR TO DISCUSS CARINA CAR-T COLLABORATION MELBOURNE Australia, 25 August 2021: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform confirms it will hold a webinar with Carina Biotech to
Slide 2: Notes to Editors: About AdAlta and Carina Biotech
Notes to Editors About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody p
Slide 3: For more information, please contact
For more information, please contact: Investors – AdAlta Media – AdAlta Tim Oldham, CEO & Managing Director IR Department Tel: +61 403 446 665 Tel: +61 411 117 774 E: t.oldham@adalta.com.au E: jane.lowe@irdepartment.com.au Investors – Carina Media – Carina Deborah Rathjen Kathy Sharrad CEO & Managin
Slide 4: Carina Biotech and AdAlta join forces to develop next-generation CAR-T cancer therapeutics
Carina Biotech and AdAlta join forces to develop unique next-generation CAR-T cancer therapeutics AUG 2021 1
Slide 5: Disclaimer
Disclaimer Investment in AdAlta Ltd (ASX:1AD) or Carina Biotech Pty Ltd (together the Parties) is subject to investment risk, including possible loss of income and capital invested. The Parties do not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capi
Slide 6: Collaboration vision
Key advantages Collaboration vision of CAR-T therapy for patients To develop precision engineered, i-body enabled, CAR-T therapies that provide new hope for patients with cancer. 3
Slide 7: What is Chimeric Antigen Receptor T (CAR-T) cell therapy?
What is Chimeric Antigen Receptor T (CAR-T) cell therapy? ✔ T akes advantage of the body’s immune response to pathogens ✔ Involves removing immune cells CAR step 1 step 2 engineered chemokine receptor from blood and re-engineering T cells T cells genetically them so they “see” cancer as a isolated f
Slide 8: Key advantages of CAR-T therapy for patients
Key advantages of CAR-T therapy for patients Can be curative Long lasting Highly targeted Even in patients whose Living therapy: a single Precision engineered cancers have returned treatment can attack to engage with tumour after multiple prior cancer over months and cells and to minimise standard t
Slide 9: A collaboration at the cutting-edge of cancer medicine
A collaboration at the cutting-edge of cancer medicine CAR engineered chemokine receptor World-leading proprietary CAR-T technologies for superior access, potency and resilience Unique i-body platform for exceptional reach and targeting capability 6
Slide 10: The i-body enabled CAR-T advantage – precision, performance and persistence
The i-body enabled CAR-T advantage – precision, performance and persistence AdAlta i-body benefits: ✔ Specifically designed to target difficult or intractable antigens ✔ Half the size of traditional CAR binding domains: greater design flexibility, ideally suited to bi-specific CARs ✔ In vitro proof
Slide 11: Bi-specific and dual targeting potential for Carina's CAR-T cells
Bi-specific and dual targeting potential for Carina’s CAR-T cells i-body i-body enabled mono-dual CAR-T cellenabled bi-specific CAR-T cell Delivering precision to difficult to treat cancers i-body enabled i-body enabled mono / dual CAR bi-specific CAR ✔ T argets 2 antigens on cancer cells engineered
Slide 12: CAR-T market opportunity
CAR-T market opportunity ✔ > $US1 billion earned by CAR-T therapy Sales and market share growth for CAR-T products3 products in 2020 ✔ R evenue of $US20.3 billion1 forecast for $1,400 25% 2028 as more CAR-T cell products are $1,200 commercialised and science evolves 20% sales (US$ million) $1,000 %
Slide 13: Existing blood cancer CAR-T products generate strong revenues, are in high demand
Existing blood cancer CAR-T products generate strong revenues, are in high demand Manufacturer 3 3 Product Notable CAR-T UPenn and Novartis Gilead acquired Kite Gilead acquired Kite Celgene acquired Juno Celgene acquired Juno transactions Alliance Aug 20122 Aug 2017 US$11.9b1 Aug 2017 US$11.9b1 Jan
Slide 14: Strong strategic fit and benefits for Carina and AdAlta
Strong strategic fit and benefits for Carina and AdAlta Benefits to Carina Benefits to AdAlta ✔ B uilds on Carina’s expertise in precision cell-based ✔ P ipeline expansion: Second external collaboration therapies for cancer treatment to follow GE Healthcare deal ✔ A ccess to bi-specific targeting fo
Slide 15: Collaboration details
Collaboration details Up to 5 targets Significant new, shared IP – Proof of principle achieved – AdAlta + Carina will jointly own collaboration IP – Targets not yet disclosed – Combine targets for bi-specific and dual-targeted CARs Post proof of concept commercialisation options Attractive deal spac
Slide 16: Next steps
Next steps Date Activity Status Prior to July 2021 Exploratory work. Establish i-body enabled CAR-T ✔ Completed cell proof of principle, select initial targets August 2021 Collaboration announced ✔ Completed H2 CY 2021 Finalise research project outlines for first two targets, commence i-body discove
Slide 17: Contacts
Contacts Carina Biotech AdAlta Pty Ltd Deborah Rathjen Tim Oldham CEO & Managing Director CEO & Managing Director Tel: +61 418 160 425 Tel: +61 403 446 665 E: deborah@carinabiotech.com E: t.oldham@adalta.com.au Kathy Sharrad Jane Lowe Communications Manager IR Department Tel: +61 415 922 914 Tel: +6
Slide 18: We're joining forces to create next generation precision therapeutics
We’re joining forces to create next generation precision therapeutics, enabling us to create new hope for patients with cancer. 15